Nijmegen, the Netherlands, 02 January 2012 - Synthon's products are a fully generic version of Roche’s Bondronat® (2mg and 6mg) and Bonviva® / Bondenza® (3mg). Bondronat® is indicated for the prevention of skeletal events in patients with breast cancer and bone metastases and treatment of tumor-induced hypercalcaemia with or without metastases. Bonviva® / Bondenza® are indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

With this regulatory clearance, Synthon is further complementing its Ibandronate product line of tablets - launched in June 2011 - and demonstrating its transition into a specialty pharmaceuticals company, with Oncology as one of the key therapeutic areas. The company has a promising pipeline of research projects and pending regulatory applications across its technological platforms of small-molecule generics, biosimilars and new biological entities.

European sales of Ibandronate for both the oncology and osteoporosis indications exceed EUR 330 million.

* Bondronat®, Bonviva® and Bondenza® are registered trademarks of F. Hoffmann-La Roche AG

About Synthon:
Synthon, with headquarters in Nijmegen, the Netherlands, is an international fast-growing pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of Multiple Sclerosis and Oncology. Synthon employs about 1,400 staff at 11 sites worldwide, and in 2010 it recorded a turnover of EUR 230 million. For more information, go to www.synthon.com.